Our pipeline – Circio

AAV gene therapy Enhanced, safer and lower cost gene therapy

Q2 '26circVec-AAV therapeutic construct PoC

2H '26CNS in vivo data

2H '26Disease model in vivo efficacy data

Heart - in house

Q2 '26circVec-AAV therapeutic construct PoC 2H '26CNS in vivo data 2H '26Disease model in vivo efficacy data

Heart in house

Eye - in house

Eye in house

CNS - pharma collaboration

CNS pharma collaboration

In vivo CAR-T Durable and re-dosable in vivo CAR-T therapy

Q2 '26T-cell delivery in vitro PoC

2H '26T-cell targeted LNP delivery in vivo

2H '26T-cell targeted CAR expression in vivo

Spleen, immune cells

Q2 '26T-cell delivery in vitro PoC 2H '26T-cell targeted LNP delivery in vivo 2H '26T-cell targeted CAR expression in vivo

Spleen immune cells

Note: Enhanced, safer and lower cost gene therapy
Program: Heart - in house
Next milestones: Q2 '26 circVec-AAV therapeutic construct PoC, 2H '26 CNS in vivo data, 2H '26 Disease model in vivo efficacy data

Technical concept

In vitro PoC

In vivo technical PoC

In vivo disease model

IND enabling

Note: Enhanced, safer and lower cost gene therapy
Program: Eye - in house

Technical concept

In vitro PoC

In vivo technical PoC

In vivo disease model

IND enabling

Note: Enhanced, safer and lower cost gene therapy
Program: CNS - pharma collaboration

Technical concept

In vitro PoC

In vivo technical PoC

In vivo disease model

IND enabling

Note: Durable and re-dosable in vivo CAR-T therapy
Program: Spleen, immune cells
Next milestones: Q2 '26 T-cell delivery in vitro PoC, 2H '26 T-cell targeted LNP delivery in vivo, 2H '26 T-cell targeted CAR expression in vivo

Technical concept

In vitro PoC

In vivo technical PoC

In vivo disease model

IND enabling

PoC: proof of concept

IND: investigational new drug

LNP: lipid nanoparticle

CAR: chimeric antigen receptor

AAV: adeno-associated virus

Subscribe